Activation of mGlu3 Receptors Stimulates the Production of GDNF in Striatal Neurons-Reference-Cited by-同舟云学术

Activation of mGlu3 Receptors Stimulates the Production of GDNF in Striatal Neurons

Published:2009-08-12 Issue:8 Volume:4 Page:e6591
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Battaglia Giuseppe,Molinaro Gemma,Riozzi Barbara,Storto Marianna,Busceti Carla L.,Spinsanti Paola,Bucci Domenico,Di Liberto Valentina,Mudò Giuseppina,Corti Corrado,Corsi Mauro,Nicoletti Ferdinando,Belluardo Natale,Bruno Valeria

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference61 articles.

1. Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders?;F Nicoletti;Trends Neurosci,1996

2. Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs.;V Bruno;J Cereb Blood Flow Metab,2001

3. Trans-1-aminocyclopentane-1,3-dicarboxylic acid (t-ACPD) decreases synaptic excitation in rat striatal slices through a presynaptic action.;DM Lovinger;Neurosci Lett,1991

4. Metabotropic glutamate receptor-mediated presynaptic depression at corticostriatal synapses involves mGLuR2 or 3.;DM Lovinger;J Neurophysiol,1995

5. In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats.;G Battaglia;Neurosci Lett,1997

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-Apoptotic and Anti-Inflammatory Properties of Grapefruit IntegroPectin on Human Microglial HMC3 Cell Line;Cells;2024-02-18

2. Epigenetic regulation of metabotropic glutamate 2/3 receptors: Potential role for ultra-resistant schizophrenia?;Pharmacology Biochemistry and Behavior;2023-08

3. Anti-apoptotic and anti-inflammatory properties of grapefruit IntegroPectin on human microglial HMC3 cell line;2023-07-23

4. Metabotropic glutamate receptors in Parkinson's disease;International Review of Neurobiology;2023

5. Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases;Pharmacology & Therapeutics;2022-11